JOHNSON & JOHNSON (JNJ) Financial Ratio Screen
Track JNJ screening changes
Get an email when this stock's published screening status or underlying ratios change.
MSCI new-inclusion financial-ratio snapshot
JNJ financial screening at a glance
Calculation date: 2026-08-31. Financial period used: December 2025. The ratios are automated proxies inspired by published methodologies; they are not official index determinations.
Independent method comparison
What the available screens say
How MSCI, FTSE and S&P-style screens differThe request button opens your email application with a pre-filled message. HalalStockGuide receives no address or request unless you choose to send it.
Business activity evidence
Activity assessment in progress
The supplied classification (Drug Manufacturers - General) is only a starting point. Revenue evidence is being assessed before any complete screening conclusion.
Revenue segments: SEC filing extraction found 52 dimensioned facts; 0 have passed extraction review. No activity conclusion is made. Open the SEC annual filing.
View SEC-extracted business segments
- Innovative Medicine — 64.1% of filing total · extraction pending
- Med Tech — 35.9% of filing total · extraction pending
- DARZALEX — 15.2% of filing total · extraction pending
- Stelara — 6.5% of filing total · extraction pending
- ELECTROPHYSIOLOGY — 6.0% of filing total · extraction pending
- GENERAL — 5.9% of filing total · extraction pending
- Surgery — 5.9% of filing total · extraction pending
- Tremfya — 5.5% of filing total · extraction pending
- ADVANCED — 4.9% of filing total · extraction pending
- CONTACTLENSESOTHER — 4.2% of filing total · extraction pending
- INVEGASUSTENNAXEPLIONTRINZATREVICTA — 4.0% of filing total · extraction pending
- Erleada — 3.8% of filing total · extraction pending
Profile description reviewed: Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Sources to verify: Secondary company profile and classification · Issuer website · SEC issuer filings
A sector label or company description can flag a risk but cannot establish a compliant-revenue percentage. Only sourced segment disclosures may support that calculation.
Published-ratio reproductions (not certifications)
The table shows implemented MSCI and FTSE/Yasaar-style asset-based models plus a provisional S&P-style leverage reconstruction where a complete 36-month denominator exists. These are independent calculations, not official index results or Shariah determinations. See formulas, sources and limitations.
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| MSCI | 24.1% / 30% | 10.1% / 30% | 20.8% / 30% | 1.12% / 5% | FINANCIAL SCREEN PASSED* |
| FTSE | 24.1% / 33% | 10.1% / 33% | 20.8% / 50% | 1.12% / 5% | FINANCIAL SCREEN PASSED* |
Financial Highlights
Profitability
| Gross Margin | 68.1% | |
| Operating Margin | 29.2% | |
| Net Margin | 21.5% | |
| Return on Equity (ROE) | 25.7% | |
| Return on Assets (ROA) | 8.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $24.5B |
| Free Cash Flow | $19.3B |
| Total Debt | $47.9B |
| Debt-to-Equity | 57.7 |
| Current Ratio | 1.1 |
| Total Assets | $199.2B |
Price & Trading
| Last Close | $267.37 |
| 50-Day MA | $254.83 |
| 200-Day MA | $231.81 |
| Avg Volume | 8.0M |
| Beta | 0.2 |
|
52-Week Range
$173.33
| |
Financial data provenance and verification
The displayed fields were imported from yfinance on 2026-08-24 for the financial period December 2025. This is a secondary data feed and can differ from amended or newly filed statements.
- Issuer website — use its investor-relations filings to verify the figures.
- SEC EDGAR filing search — primary filing source for US issuers.
- Field mapping, formulas and limitations.
Verification rule: check debt, cash, receivables, revenue and interest income against the latest primary filing before relying on an automated ratio.
About JOHNSON & JOHNSON (JNJ)
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Popular halal stock checks
Explore other frequently viewed automated stock screens and compare the available financial ratios.
Frequently Asked Questions
Is JOHNSON & JOHNSON (JNJ) halal to invest in?
The current automated result is Financial screen passed; activity assessment pending. It uses available public financial fields and simplified methodology proxies. It is not a fatwa or an official determination by AAOIFI, DJIM, MSCI, S&P, or FTSE.
What is JOHNSON & JOHNSON's debt ratio?
JOHNSON & JOHNSON's debt ratio is 24.1% in the MSCI new-inclusion reproduction: total debt divided by total assets, against a 30% threshold. See the methodology page for the official source and limitations.
What are JOHNSON & JOHNSON's key financial metrics?
JOHNSON & JOHNSON has a market capitalization of USD 651251M in its listing currency, trailing P/E ratio of 31.4, and revenue of $94.2B. The company maintains a gross margin of 68.1% and a net margin of 21.5%. Return on equity stands at 25.7%.
How often is the screening data updated?
Calculation date: 2026-08-31. Financial period: December 2025. These dates are shown separately because regenerating this page does not refresh the underlying data.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.